A Review of the Diagnosis and Treatment of Necrotizing Enterocolitis.


Journal

Current pediatric reviews
ISSN: 1875-6336
Titre abrégé: Curr Pediatr Rev
Pays: United Arab Emirates
ID NLM: 101240290

Informations de publication

Date de publication:
2023
Historique:
received: 07 03 2022
revised: 22 04 2022
accepted: 27 05 2022
pubmed: 6 8 2022
medline: 9 2 2023
entrez: 5 8 2022
Statut: ppublish

Résumé

Necrotizing enterocolitis (NEC) is a devastating disease that primarily affects the gastrointestinal tract of premature neonates. The diagnosis and treatment of NEC remain challenging. New biomarkers and potential treatments for NEC have emerged in recent years, leading to the potential of earlier therapeutic intervention and improved outcomes. This paper aims to provide a review of the most recent diagnostic indicators and therapeutics of NEC along with a brief overview of future directions of research into this disease.

Identifiants

pubmed: 35929629
pii: CPR-EPUB-125363
doi: 10.2174/1573396318666220805110947
doi:

Substances chimiques

Biomarkers 0

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

285-295

Subventions

Organisme : Oklahoma Shared Clinical and Translational Resources
ID : 20002060

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Xue Cai (X)

Department of Surgery, The University of Oklahoma Health Sciences Center, 800 Research Parkway Suite 449, Oklahoma City, OK 73104, Japan.

Heather L Liebe (HL)

Division of Pediatric Surgery, Oklahoma Children's Hospital, Oklahoma City, OK 73104, Japan.

Alena Golubkova (A)

Division of Pediatric Surgery, Oklahoma Children's Hospital, Oklahoma City, OK 73104, Japan.

Tyler Leiva (T)

Division of Pediatric Surgery, Oklahoma Children's Hospital, Oklahoma City, OK 73104, Japan.

Catherine J Hunter (CJ)

Division of Pediatric Surgery, Oklahoma Children's Hospital, Oklahoma City, OK 73104, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH